Developing game changing treatments and cell therapies for severe diseases

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our drug canditates have the potential to improve outcomes in the treatment of neurological and ophthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.

“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”

Professor Ann LoganScientific Director, Neuregenix Ltd.

News

TikoMed announces the publication of results from an open-label, single arm, single center phase II trial carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team in patients with confirmed Amyotrophic Lateral Sclerosis (ALS) treated with weekly ILB® injections.

22 July, 2024

The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have officially signed a research collaboration agreement.

27 June, 2024

The Division of Clinical Neuroscience vid Oslo universitetssjukhus och det svenska biofarmabolaget TikoMed har officiellt undertecknat ett forskningssamarbetsavtal.

27 June, 2024

Events

TikoMed will be at BIO Europe Spring 2024

7 March, 2024

TikoMed Presenting at ALS ONE Annual Symposium

17 November, 2023

TikoMed attended the NEALS Clinical Trials Workshop in Cambridge, US

3 April, 2023

Science & pipeline

ILB – Neurology

ILB has the potential to treat neurodegenerative diseases for good

IBSOLVMIR – Cell therapy

IBSOLVMIR can improve the effects of cell therapy